UT-MD Anderson Cancer Center: ASCO - Novel Targeted Cancer Therapies Demonstrate Activity and Safety in Metastatic Solid Tumors
June 03, 2024
June 03, 2024
HOUSTON, Texas, June 3 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
MD Anderson researchers share preliminary clinical data of an antibody-drug conjugate for metastatic colorectal cancer and a USP1 inhibitor for advanced solid tumors
* * *
ABSTRACTS: 3000 (https://meetings.asco.org/abstracts-presentations/231480) and 3005 (https://meetings.asco.org/abstracts-presentations/231487)
. . .
* * *
MD Anderson researchers share preliminary clinical data of an antibody-drug conjugate for metastatic colorectal cancer and a USP1 inhibitor for advanced solid tumors
* * *
ABSTRACTS: 3000 (https://meetings.asco.org/abstracts-presentations/231480) and 3005 (https://meetings.asco.org/abstracts-presentations/231487)
. . .